The GLP-1 Paradox—Why Is a $95B Obesity Market Ignoring Its Biggest Problem?

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall obesity market unless we approach the problem head on.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top